NXL Latest Press Releases

-- October 27, 2026 --

Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease Globe Newswire 9:00 AM

-- October 8, 2026 --

Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing Globe Newswire 8:30 AM

-- October 1, 2026 --

These Stocks Roar into October with Fresh Catalysts Globe Newswire 12:39 PM

Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation Globe Newswire 8:30 AM

-- September 29, 2026 --

Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy Globe Newswire 9:00 AM

-- September 3, 2026 --

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study Globe Newswire 8:30 AM

-- August 27, 2026 --

Nexalin Technology Announces Reverse Stock Split Globe Newswire 7:25 AM

-- June 23, 2026 --

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS Platform Globe Newswire 8:30 AM

-- June 16, 2026 --

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life Globe Newswire 9:15 AM

-- June 10, 2026 --

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. Globe Newswire 9:15 AM

-- June 4, 2026 --

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia Globe Newswire 10:00 AM

Market Data Delayed 15 Minutes